Daniel Horton is a pediatric rheumatologist and pharmacoepidemiologist who performs clinical, translational, and health services research. He started at Rutgers in 2016 as an Assistant Professor and Chancellor’s Scholar in the Department of Pediatrics at Rutgers Robert Wood Johnson Medical School and was a founding faculty member of PETS in 2017. He is currently Associate Professor with Tenure and an adjunct faculty member in the Department of Biostatistics and Epidemiology at the Rutgers School of Public Health. He graduated from Harvard Medical School (MD, 2008) and completed pediatrics residency at the Children’s Hospital of Philadelphia (2011), followed by pediatric rheumatology fellowship at Nemours/A.I. duPont Hospital for Children (2014) and research training in clinical epidemiology and pharmacoepidemiology at the University of Pennsylvania (MSCE, 2015). Broadly, Dr. Horton’s research focuses on the uses, safety, and effectiveness of medications in children, with particular interests in antibiotics, anti-inflammatories, and anti-rheumatic drugs. He performs research on the origins and treatment of juvenile idiopathic arthritis, including the role of antibiotics, the microbiome, and the management of disease remission. He has conducted clinical, translational, and interventional research on COVID-19 in pediatric and adult populations. His work has been published in Pediatrics, JAMA Pediatrics, Arthritis and Rheumatology, Annals of Rheumatic Diseases, American Journal of Epidemiology, Circulation, Proceedings of the National Academy of Sciences, and elsewhere. Dr. Horton’s research has been supported by grants from the National Institutes of Health (NIAMS, NIAID, NCATS, NICHD) as well as various research foundations. At Rutgers, Dr. Horton serves as the Faculty Director of the IFH Survey / Data Core. Chair of the PETS Faculty Search Committee, Co-Chair of the Pediatric Resident Scholarly Oversight Committee, Director of the Clinical Epidemiology Certificate Program at the School of Public Health, and Co-Leader of the Team Science Core of NJ ACTS (CTSA). He has held leadership positions within the International Society for Pharmacoepidemiology and the Childhood Arthritis and Rheumatology Research Alliance, is a consultant to the FDA Drug Safety and Risk Management Advisory Committee, and is Associate Editor for the journal, Pharmacoepidemiology and Drug Safety.
Pharmacoepidemiology, Health Services Research, Translational Research, Health Outcomes, Pediatrics, Juvenile Idiopathic Arthritis, Glucocorticoids, Antibiotics, Microbiome, Deprescribing, Off-label Use, COVID-19, Multisystem Inflammatory Syndrome in Children
- Ringold S, Dennos AC, Kimura Y, Beukelman T, Shrader P, Phillips TA, Kohlheim M, Schanberg LE, Yeung RS, Horton DB. Disease Recapture Rates After Medication Discontinuation and Flare in JIA: An Observational Study within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care & Research, 2023; 75(4):715-723.
- Horton DB°, Barrett ES° (°equal contributions), Roy J, Gennaro ML, Andrews T, Greenberg P, Bruiners N, Datta P, Ukey R, Velusamy SK, Fine D, Honnen WJ, Yin YS, Pinter A, Brooks A, Tischfield J, Hussain S, Jagpal S, Swaminathan S, Parmar V, Reilly N, Gaur S, Panettieri RA Jr*, Carson JL*, Blaser MJ* (*equal contributions). Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study. Journal of Infectious Diseases, 2021;224(8):1345-1356. PMCID: PMC8436370.
- Horton DB, Xie F, Chen L, Mannion ML, Curtis JR, Strom BL, Beukelman T. Oral glucocorticoids and incident treatment of diabetes mellitus, hypertension, and venous thromboembolism in children. American Journal of Epidemiology, 2021; 190(3):403-412. PMCID: PMC8086240.
- Horton DB, Salas J, Wec A, Kapadia P*, Beukelman T, Boneparth A, Haverkamp K, Kohlheim M, Mannion M, Moorthy LN, Ringold S, Rosenthal M. Making decisions about stopping medicines for well-controlled juvenile idiopathic arthritis: a mixed-methods study of patients and caregivers. Arthritis Care & Research, 2021; 73(3):374-385. PMCID:PMC7319899.
- Hoon D, Taylor MT, Kapadia P, Gerhard T, Strom BL, Horton DB. Trends in off-label drug use in ambulatory settings: 2006-2015. Pediatrics 2019; 144(4): e20190896. PMCID: PMC7286122.
- Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, Strom BL. Antibiotic exposure and juvenile idiopathic arthritis: a case-control study. Pediatrics 2015; 136(2): e333-343. PMCID: PMC4516942.
September 2022 – May 2027
Safety of Drugs Commonly Used Off-Label in Children Despite Insufficient Evidence of Efficacy and Safety
April 2022 – April 2024
Pilot of Adalimumab Withdrawal (PAW)
Childhood of Arthritis and Rheumatology Research Alliance-Arthritis Foundation
September 2021 – August 2024
Cohort and biomarkers for COVID-19 severity, natural history, and reinfection
July 2021 – June 2023
New Jersey Kids Study
State of New Jersey
Member, Executive Committee
January 2021 – November 2024
COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict
Severe Illness in Children (CONNECT to Predict Sick Children)
August 2019 – June 2023 (no-cost extension through June 2024)
Antibiotics, juvenile idiopathic arthritis, and antirheumatic treatment response
March 2019 – February 2024
New Jersey Alliance for Clinical and Translational Science: NJ ACTS
Co-Leader, Team Science Core
February 2021 – December 2022
Live Microbials to Boost Anti-SARS-CoV-2 Immunity Clinical Trial (Live BASIC Trial)
Danisco USA Inc.
September 2020 – February 2022
New Jersey Healthcare Essential WoRker Outreach and Education Study – Testing Overlooked Occupations (NJ HEROESYOO)
July 2020 – February 2021
Supplement to New Jersey Alliance for Clinical and Translational Science: NJ ACTS
May 2020 – October 2020
Cohort study of SARS-CoV-2 incidence, risk factors, and disease severity in healthcare workers
November 2019 – July 2021
Disease recapture after drug discontinuation and flare in JIA
Rheumatology Research Foundation
August 2018 – July 2019
Stopping medicines for juvenile idiopathic arthritis: perspectives of patients and families
Childhood Arthritis & Rheumatology Research Alliance-Arthritis Foundation
May 2017 – February 2018
A comparison of record linkage software and algorithms using real-world data
Bristol-Myers Squibb, Subcontract from RTI
September 2016 – August 2021
Drugs, germs, and joints: antibiotics, gut microbiota, and juvenile idiopathic arthritis
July 2014 – June 2015
Glucocorticoid use and osteonecrosis in chronic pediatric inflammatory diseases